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Abstract: It is estimated that approximately a quarter of patients undergoing coronary intervention 
may have signifi cant post-procedural creatinine (CK)/creatinine kinase myocardial band (CK-MB) 
elevations and approximately half may have post-procedural troponin elevations. Current data sug-
gest that periprocedural infarction is associated with short-, intermediate-, and long-term adverse 
outcomes, most notably mortality. This review examines the role of clopidogrel in decreasing 
periprocedural myonecrosis following percutaneous coronary intervention (PCI). Clopidogrel is 
an important pharmacologic agent used to reduce myocardial infarction post-coronary intervention 
as assessed directly by the evaluation of cardiac biomarkers and indirectly by the evaluation of 
short-term ischemic events. The optimal dose of clopidogrel is considered to be at least 300 mg 
given 6 to 15 hours prior to PCI but there is considerable evidence to suggest that a loading dose 
of 600 mg given 2 to 6 hours prior to PCI may be more effi cacious in limiting post-coronary inter-
vention events. The benefi t obtained from clopidogrel appears independent of and incremental to 
that of other antiplatelet and antithrombotic agents used during and after coronary intervention.
Keywords: percutaneous coronary intervention, myonecrosis, clopidogrel, antiplatelet agents, 
myocardial infarction
Introduction
Percutaneous coronary intervention (PCI) has become the most common form of 
coronary revascularization in the United States with greater than 900,000 procedures 
performed annually.1 Although overall a safe procedure, PCI does have multiple asso-
ciated risks including bleeding, coronary dissection, and abrupt vessel closure. These 
complications are obviously undesirable and intuitively associated with negative long-
term outcomes but an even more frequent and important contributor to the mortality 
and morbidity associated with PCI is periprocedural myonecrosis and infarction.2 The 
defi nition of periprocedural myocardial infarction was standardized in 2007 with a 
post-procedure elevation of cardiac biomarkers more than 3 times the 99th percentile 
upper reference limit (URL) defi ned as PCI-related myocardial infarction (MI).3 It is 
estimated that approximately 25% of patients undergoing PCI have signifi cant post-
procedural creatinine (CK)/creatinine kinase myocardial band (CK-MB) elevations and 
approximately 50% of patients have signifi cant post-procedural troponin elevations.2 
Initially, it was felt these elevations were simple enzyme leaks with no long-term 
implications. Multiple data sets have now defi nitively demonstrated that periprocedural 
infarction is associated with short-, intermediate-, and long-term adverse outcomes, 
most notably mortality.4–7 This review examines the role of clopidogrel in decreasing 
periprocedural myonecrosis following PCI.
Pathophysiology of periprocedural myonecrosis 
and the role of clopidogrel therapy
PCI invariably results in mechanical plaque disruption with some degree of associ-
ated endothelial injury. Platelet attachment then occurs at the site of endothelial 
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injury through platelet surface interactions with the exposed 
extracellular matrix (ECM) and exposed von Willebrand 
Factor (vWF).8 Following platelet attachment, a series of 
platelet activating steps occur including the secretion of vari-
ous secondary messengers including ADP, thromboxane A2, 
and serotonin.9 These messengers result in further auto-
activation of platelets and subsequent platelet morphological 
changes resulting in fi rm platelet adhesion, activation of 
thrombin, and eventual full platelet aggregation via the 
glycoprotein IIb/IIIa integrin receptor.10 Local vasoconstric-
tion and infl ammation, combined with the accumulation and 
embolization of platelet aggregates, results in thrombosis, 
ischemia, and infarction in the microvascular circulation.11 
Endogenous release of vasodilators such as adenosine is 
able to compensate to some degree but when suffi cient 
platelets aggregate, they are able to exceed all compensatory 
mechanisms and the result is periprocedural myonecrosis 
and/or infarction. This highlights the importance of plate-
let-dependent processes in the pathophysiology of ischemic 
complications following PCI.
This importance of platelet activity in post-PCI ischemic 
complications was clinically demonstrated by the Intracoro-
nary Stenting and Antithrombotic Regimen (ISAR) trial, Full 
Anticoagulation Versus Ticlopidine plus Aspirin after Stent 
Implantation (FANTASTIC) trial, and Stent Anticoagulation 
Regimen Study (STARS) trials.12–14 Each trial demonstrated 
the superiority of an anti-platelet approach (aspirin and/or 
ticlopidine) over anticoagulation in the reduction of the com-
posite endpoint of cardiovascular (CV) death, MI, or need 
for recurrent revascularization following stent placement and 
specifi c post-procedural outcomes such as early stent throm-
bosis. These trials helped established the role of anti-platelet 
therapy in reducing both periprocedural and post discharge 
ischemic complications following PCI.
Three key classes of anti-platelet agents are used currently 
in clinical practice: aspirin, intravenous glycoprotein IIb/IIIa 
inhibitors, and thienopyridines. The thienopyridine class of 
antiplatelet agents is composed of ticlopidine, clopidogrel, 
and prasugrel which is under FDA review. These drugs 
act through non-competitive, irreversible antagonism of 
the ADP binding site on the P2Y12 receptor on platelets.15 
Ticlopidine’s use was limited by its twice-daily formulation 
and by the main side effects of occasional neutropenia, and 
even more rarely thrombotic thrombocytopenia purpura 
(TTP).15 Clopidogrel is a second generation thienopyridine 
agent with an oral formulation requiring gastrointestinal 
absorption mediated by the P-glycoprotein effl ux pump 
followed by a 2 step cytochrome p-450 dependent activation 
resulting in the active metabolite.16 The use of clopidogrel 
in place of ticlopidine began in 2000, after the Clopidogrel 
Aspirin Stent International Cooperative Study (CLASSICS) 
trial demonstrated better tolerability profi le with no change 
in the rates of recurrent ischemic events.17
Clopidogrel and present data
In the current era, clopidogrel’s important pharmacothera-
peutic role has been expanded to include patients undergo-
ing PCI for any indication including non-ST elevation acute 
coronary syndrome (NSTE ACS), routine elective PCI, and 
ST elevation myocardial infarction (STEMI). The evidence 
for this comes from three main trials: Effects of Pretreat-
ment with Clopidogrel and Aspirin Followed by Long-Term 
Therapy in Patients Undergoing Percutaneous Coronary 
Intervention: the PCI-CURE Study (PCI-CURE), Early 
and Sustained Dual Oral Antiplatelet Therapy Following 
Percutaneous Coronary Intervention: A Randomized Con-
trol Trial (CREDO), and Effect of Clopidogrel Pretreatment 
Before Percutaneous Coronary Intervention in Patients wit 
ST-Elevation Myocardial Infarction Treated with Fibri-
nolytics: the PCI-CLARITY Study (PCI-CLARITY).18–20 
These trials demonstrated the clear and consistent benefi t 
of clopidogrel, specifi cally clopidogrel pretreatment, in 
the prevention of ischemic complications post-PCI. These 
trials also helped clarify the optimal timing of clopidogrel 
pretreatment in limiting thrombotic and ischemic compli-
cations post PCI.
PCI-CURE aimed to investigate whether pretreatment 
followed by long term administration of clopidogrel with PCI 
was superior to no clopidogrel pretreatment and short-term 
clopidogrel therapy in terms of reducing post-PCI ischemic 
events. The study examined outcomes in 2658 patients with 
NSTE-ACS enrolled in the original Clopidogrel in Unstable 
Angina to prevent Recurrent Events (CURE) trial21 who 
underwent angiography and PCI at the discretion of the 
treating physician. These patients had been randomized at 
presentation to clopidogrel (N = 1313) or placebo (N = 1345) 
with a 300 mg loading dose followed by 75 mg daily per 
CURE trial protocol. Patients received pretreatment with 
clopidogrel for a mean of 6 days prior to angiography. 
Following PCI, 80% of patients in both groups received 
open-label thienopyridine for 4 weeks, after which the study 
drug (placebo versus clopidogrel) was restarted for a mean 
of 8 months.
The primary endpoint was a composite of CV death, 
MI, or urgent target-vessel revascularization (TVR) within 
30 days of PCI. Although the study did not directly assess for 
Vascular Health and Risk Management 2009:5 277
Clopidogrel during PCI
periprocedural MI rates through routine screening for 
post-procedure increases in cardiac enzymes, the results did 
suggest a marked decrease in this outcome. The study found 
a signifi cant decrease in the primary composite endpoint 
in the clopidogrel group versus the placebo group (4.5% 
versus 6.4%; p = 0.03). This difference was driven mostly 
by a decrease in the number of MIs (2.1% versus 3.8%) and 
specifi cally q-wave MIs (0.8% versus 2.4%) post PCI. CV 
death and urgent TVR rates were statistically similar between 
the two groups. This lower rate of the primary endpoint was 
seen as early as 2 days after PCI implicating a reduction in 
periprocedural MI and the benefi t continued until 30 days 
(Figure 1). As both groups of patients received clopidogrel 
post PCI for at least 30 days at equally high rates, the benefi t 
of the marked reduction in periprocedural MI was likely due 
to the effects of clopidogrel pre-treatment with a 300 mg load 
followed by a 75 mg daily dose given a mean of 6 days prior 
to PCI. Thus although this study fi rst highlighted the impor-
tance of clopidogrel loading prior to PCI to help decrease 
PCI-related myonecrosis, the optimal timing of this loading 
dose was not yet clear.
The CREDO study19 randomized 1815 patients 
undergoing planned PCI to 300 mg clopidogrel loading 
at presentation (N = 900) versus placebo loading at pre-
sentation (N = 915) with subsequent clopidogrel daily in 
both groups through day 28. Following this, the clopido-
grel loading group continued on clopidogrel from day 29 
through 12 months while the placebo group was restarted 
on placebo. Both groups had routine evaluation for peri-
procedural MI defi ned as an elevation in the CK or CK-MB 
levels to at least 3 times the upper limit of normal (ULN) 
in 2 samples collected at different sampling times. At 
28 days, the composite endpoint of death, MI, and urgent 
TVR was assessed in both groups. The mean duration 
between clopidogrel loading and PCI was 9.8 hours but 
with 51% of patients receiving their load less than 6 hours 
before PCI.
Clopidogrel loading was associated with a non-signifi cant 
decrease in the composite endpoint at 28 days (6.8% pre-
treatment versus 8.3% no pretreatment, p = 0.23, Figure 2). 
For each individual component of the combined end point, 
there were fewer events in patients receiving clopidogrel 
pretreatment. When the groups were re-analyzed based on 
the prespecifi ed loading time intervals of 3 to 6 hours, 6 to 
12 hours, and 12 to 24 hours prior to PCI, an important 
interaction was noted between the timing of pretreatment 
and reduction in the composite endpoint. Patients receiving 
clopidogrel between 3 and 6 hours prior to PCI had no 
benefi t compared to placebo whereas patients treated 6 to 
12 and 12 to 24 hours before PCI had progressively increased 
protection from adverse cardiac events at 28 days. Patients 
who received a 300 mg clopidogrel loading at least 6 hours 
before PCI experienced a 38.6% relative reduction in the 
composite endpoint at 8 days that was of borderline statistical 
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Figure 1 Kaplan Meier cumulative event rates for primary endpoint at 30 days after PCI in the PCI CURE study. Reprinted from The Lancet, 358, Mehta SR, Yusuf S, Peters RJ, 
et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, 
527–533,18 Copyright © 2001, with permission from Elsevier.
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signifi cance (p = 0.051, Figure 2). In a subsequent analysis of 
these data, the CREDO investigators found that the benef it of 
clopidogrel loading became highly signifi cant when admin-
istered at least 15 hours prior the procedure.22 Thus CREDO 
expanded the indication for clopidogrel therapy to a more 
stable ischemic population group and also suggested the 
optimal clopidogrel therapy prior to PCI in terms of reduction 
of periprocedural thrombotic events was a loading dose of 
300 mg given at least 6 hours and optimally 15 hours prior 
to PCI followed by a maintenance daily dose.
PCI-CLARITY20 examined the outcomes of 1863 patients 
with STEMI who per study protocol had received fi brinolytic 
therapy followed by routine angiography and then underwent 
PCI at the discretion of the treating physician. These patients 
had been randomly assigned to clopidogrel (N = 933) or 
placebo (N = 930) prior to angiography. Patients randomized 
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Figure 2 CREDO combined end points at 28 Days. Reproduced with permission from Steinhubl et al. JAMA. 2002;288(19):2411–2420.19 Copyright © 2005 American Medical 
Association.  All rights reserved.
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to clopidogrel received a 300 mg loading dose followed by 
75 mg per day with the load being given within 45 minutes of 
the start of fi brinolytic therapy. The primary effi cacy outcome 
was a composite of CV death, recurrent MI, or stroke from 
the time of PCI to 30 days after randomization. CK-MB was 
measured 3 times over 24 hours following intervention to 
ensure systematic monitoring for post-PCI MI which was 
defi ned as CK-MB of at least 3 times ULN and if CK-MB 
was already elevated, a CK-MB increase by 50% over the 
previous value. The median number of days of clopidogrel 
administration prior to PCI was 3 days.
Pretreatment with clopidogrel signifi cantly reduced the 
rate of CV death, MI, or stroke following PCI through 30 days 
after randomization (3.6% versus 6.2%, p = 0.008). The 
benefi t of pretreatment was directionally consistent among 
all the components of the composite end point. Event curves 
revealed the two treatment groups separated soon after PCI 
and continued to diverge over time (Figure 3). Even though 
the median duration of time between randomization and PCI 
was 3 days, the benef it of pretreatment seemed consistent 
across the broad range of pretreatment durations ranging 
from 6 hours to 8 days.
Taken together, the PCI-CURE, CREDO, and PCI-
CLARITY studies demonstrated a consistent benefi t with 
clopidogrel pretreatment in terms of reduction of short-
term cardiac events following PCI (Figure 4). As CREDO 
and PCI-CLARITY specifi cally examined and included 
periprocedural MI in their short term composite primary 
endpoint analysis, the use of clopidogrel certainly suggests 
a reduction in this event while analysis of PCI-CURE sug-
gested a decrease in short-term events driven specifi cally by 
a decrease in periprocedural MIs.
The benef it of clopidogrel in PCI in terms of reduction 
of myocardial necrosis is demonstrated in reduced short term 
cardiac events but also can be inferred from the higher rates 
of TIMI 3 f low seen in patients who receive clopidogrel pre-
treatment. In PCI-CLARITY, a higher percentage of patients 
receiving clopidogrel versus placebo had TIMI 3 fl ow at the 
time of their protocol mandated angiography.20 A meta-analysis 
of 38 trials comparing patients with STEMI treated with PCI 
receiving clopidogrel pretreatment versus placebo found simi-
lar results with a highly signifi cant increase in TIMI 3 f low in 
patients pretreated with clopidogrel (OR 1.53, p  0.0001).23 
This meta-analysis also confi rmed the signifi cant decrease in 
short term (42 days) mortality and death/reinfarction seen 
PCI-CURE, CREDO, and PCI-CLARITY when patients were 
pretreated with clopidogrel (Figure 5).
These studies demonstrate the importance of clopidogrel 
pretreatment in terms of reducing periprocedural myonecrosis 
and associated short term cardiac events and is the basis 
for the current American College of Cardiology (ACC)/
American Heart Association (AHA) class 1 recommenda-
tion for the use of clopidogrel pretreatment with a 300 mg 
loading dose given at least 6 hours before PCI in patients 
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Figure 3 Outcomes at 30 days in the PCI-CLARITY study. Reproduced with permission from Sabatine et al. JAMA. 2005;294(10):1224–1232.20 Copyright © 2005 American 
Medical Association.  All rights reserved.
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with acute coronary syndrome as well as in those undergoing 
elective intervention.24
Optimal pre-treatment dose: higher 
loading dose and chronic therapy
Observational data demonstrated that a 600 mg loading dose 
of clopidogrel caused an earlier and stronger inhibition of 
adenosine diphosphate (ADP)-induced platelet activation 
than a 300 mg loading dose.25,26 Based on these studies, the 
Antiplatelet Therapy for Reduction of Myocardial Damage 
during Angioplasty (ARMYDA-2) study was carried out to 
test the hypothesis of whether a higher loading dose of 600 mg 
clopidogrel would reduce post-PCI events compared to a 
standard 300 mg dose in patients undergoing elective PCI.27 
A total of 329 patients scheduled for PCI were randomized 
to a 600 mg (N = 163) or 300 mg (N = 166) loading regimen 
of clopidogrel given 4 to 8 hours (mean of 6 hours) before 
the procedure. The primary endpoint of the study was 30-day 
occurrence of death, MI, or TVR. CK-MB, troponin I, and 
myoglobin levels were measured at baseline and at 8 and 
24 hours after PCI and the secondary end points included any 
post-procedural increase of these markers above the ULN. 
The primary endpoint occurred in 4% of patients in the 
high loading dose versus 12% in the standard loading group 
(p = 0.041). This reduction in the primary endpoint was driven 
entirely by a decrease in rates of periprocedural MI; 15 MI 
occurred in the 300 mg group versus 5 in the 600 mg group. 
Peak values of all cardiac biomarkers were signifi cantly lower 
in patients treated with the 600 mg regimen (Figure 6).
The ARMYDA-2 study suggested patients given a 
600 mg loading dose of clopidogrel 6 hours prior to PCI 
experienced fewer periprocedural MI than those receiv-
ing a 300 mg loading dose. The majority of patients in 
both arms of the ARMYDA-2 study were low risk stable 
angina patients (75% in both high and conventional load-
ing dose arms). When the higher loading 600 mg dose was 
tested exclusively in higher risk patients with NSTE-ACS, 
similar superior outcomes at 1 month post-PCI was noted 
in the high-risk patients given 600 mg loading dose versus 
conventional 300 mg dose; a 1-month follow up period 
revealed recurrent cardiovascular events occurring at 5% 
and 12% respectively (p = 0.02).28 A meta-analysis con-
ducted by Lotrionte et al29 further investigated the benefi t 
of high dose clopidogrel loading versus standard 300 mg 
0.25                  0.5                   1.0                    2.0
Favors
Pretreatment
Favors No
Pretreatment
P = 0.004
Source              Clopidogrel          Placebo            OR (95% CI)
PCI-CURE
CREDO
PCI-CLARITY
Overall
38/1313 (2.9) 59/1345 (4.4) 0.65 (0.43–0.98)
54/9000 (6.0) 65/915 (7.1) 0.83 (0.57–1.21)
31/933 (3.3) 50/930 (5.4) 0.60 (0.38–0.96)
123/3146 (3.9) 174/3 190 (5.5) 0.71 (0.56–0.89)
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Figure 5 Meta-analysis of clopidogrel pretreatment in STEMI patients undergoing PCI with respect to short-term outcomes. Reproduced with permission from Vlaar PJ, 
Svilaas T, Damman K, et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for 
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loading in patients undergoing PCI. The meta-analysis 
included 10 trials (7 randomized and 3 non-randomized) 
with a total of 1567 patients enrolled. Overall, a high loading 
dose (300 mg) proved signifi cantly superior to a standard 
loading dose in terms of reducing early cardiac death or 
non-fatal MI post PCI (odds ratio 0.54, p = 0.02). This 
analysis also found that patients at highest risk, defi ned by 
the presence of elevated cardiac biomarkers, benefi ted the 
most with the increased loading dose.
Although these studies suggest the benefi cial role for a 
600 mg clopidogrel loading dose versus the 300 mg loading 
dose, the optimal timing of the higher dose is somewhat 
controversial. In the ARMYDA-2 trial, the 600 mg loading 
dose was given between 4–8 hours with a mean of 6 hours 
prior to PCI suggesting the optimal timing is 6 hours prior 
to intervention. Platelet functional studies have shown that 
the 600 mg dose of clopidogrel achieves maximal platelet 
inhibition 2 hours after administration.30 This has led to the 
overall consensus that the 600 mg loading dose should be 
given at least 2 hours, and optimally 6 hours, prior to PCI.
The Intracoronary Stenting and Antithrombotic Regimen: 
Choose Between 3 High Oral Doses for Immediate Clopi-
dogrel Effect (ISAR-CHOICE) trial investigated whether 
loading doses higher than 600 mg of clopidogrel exerted 
additional suppression of platelet function.31 The study 
compared the effects of 300, 600, and 900 mg clopidogrel 
doses on platelet function among stable patients scheduled 
for coronary angiography. Sixty patients were assigned to 
1 of 3 clopidogrel loading schemes in a randomized, double 
blinded manner. Optical aggregometry was performed 
before and 4 hours after administration of clopidogrel. At 
4 hours, patients treated with both 600 and 900 mg doses 
demonstrated greater inhibition of platelet aggregation (IPA) 
than the 300 mg dose. No signifi cant difference in platelet 
inhibition was found between the 600 and 900 mg doses. On 
the basis of this fi nding, the ISAR-CHOICE trial concluded 
that single clopidogrel loading dosages 600 mg was not 
associated with any additional suppression of platelet activ-
ity. The trial also found, through the measured levels of clopi-
dogrel metabolites in the differing loading dose schemes, 
that the maximal clopidogrel loading dose of 600 mg was 
perhaps related to impaired intestinal absorption beyond the 
600 mg dose.31
The Assessment of the Best Loading Dose of Clopidogrel 
to Blunt Platelet Activation, Infl ammation, and Ongoing 
Necrosis (ALBION) trial, in contrast to ISAR-CHOICE 
found that there was greater platelet inhibition with 900 mg 
loading dose of clopidogrel compared to 600 mg loading 
dose in reference to the 300 mg baseline loading dose.32 
The ALBION study assessed platelet aggregation through 
standard ADP induced optical aggregometry in 35 patients 
randomized to 300 mg, 34 patients randomized to 600 mg, 
and 34 patients randomized to 900 mg clopidogrel. Platelet 
aggregometry was measured 8 times in the fi rst 6 hours and 
the study found increased inhibition of platelet activity (IPA) 
at higher loading dosage compared to standard dose with near 
equal time to maximal effect at 5 to 6 hours. It should be 
noted that no direct comparison of degree of platelet inhibi-
tion was made between the 600 mg and 900 mg doses. The 
trial was too small to assess clinical outcomes but did suggest 
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that increased loading dosages may be useful in higher risk 
patients as there was increased platelet inhibition.
A related question of clopidogrel dosing involves whether 
patients who are already receiving a maintenance dose of 
clopidogrel should receive a booster load. The ARMYDA-4 
study examined the effi cacy of a reloading dose of clopido-
grel in patients with stable angina or NSTE-ACS undergoing 
PCI who were on chronic clopidogrel therapy.33 Investigators 
followed patients randomly assigned to a reload arm 
(N = 180) with a 600 mg clopidogrel load given 4 to 8 hours 
prior to PCI versus patients randomly assigned to a placebo 
arm (N = 180). The primary endpoint was a composite of 
death, MI, and TVR at 30 days. The secondary endpoints 
included increase in post-procedure biomarkers, peak values 
of myocardial enzymes, point of care evaluation of platelet 
activity, and bleeding complications. The composite primary 
endpoint was identical in the reload and placebo arms (8% 
versus 7%). The primary endpoint was driven exclusively 
by MI as there were no deaths and no TVR. Myocardial 
markers, platelet aggregometry, and bleeding complications 
were also identical in both arms. This study concluded that 
patients on chronic clopidogrel did not require reloading 
prior to PCI.
The main limitations of the ARMYDA-4 study included 
its small size and the fact that the majority of the enrolled 
patients were relatively stable with less than one third of the 
patients presenting with ACS. Subsequently, the ARMYDA-
RELOAD study examined a higher risk population of patients 
taking chronic clopidogrel therapy.33 The study followed 
436 patients on chronic clopidogrel therapy (at least 10 days) 
of which 167 patients had presented with ACS and exam-
ined the effect of reloading with 600 mg clopidogrel versus 
placebo on post-PCI outcomes. The primary endpoint was a 
composite endpoint of death, MI, and TVR at 30 days. Platelet 
reactivity was also measured in both groups. Overall, there 
was again no demonstrable difference in the primary endpoint 
between the 2 groups (7% clopidogrel reload arm versus 9% 
in placebo arm, p = 0.7) but when the ACS subgroup was ana-
lyzed alone, there was a signifi cant reduction in the primary 
endpoint in the reload arm (7% versus 18%, p = 0.035). 
Platelet reactivity was also signifi cantly lower in the ACS 
subgroup receiving a 600 mg reload. Thus although this study 
was essentially negative, it did suggest the benefi cial role of 
a 600 mg reload given 4 to 8 hours prior to PCI in patients 
on chronic clopidogrel therapy presenting with ACS.
In the Dose Effect of Clopidogrel Reloading in Patients 
Already on 75 mg Maintenance Dose: the Reload With Clopi-
dogrel Before Angioplasty in Subjects Treated Long Term 
With Dual Antiplatelet Therapy (RELOAD) Study, Collet et al 
examined whether patients on chronic clopidogrel benefi ted 
from a 900 mg reload dose.34 The dosage scheme of reloading 
was given in 3 different strategies allowing further examina-
tion of the hypothesis raised by ISAR-CHOICE that there was 
a maximal absorption threshold of 600 mg which limited the 
benefi t of higher load dosing schemes. The study’s primary 
endpoint was inhibition of platelet activity as measured by opti-
cal aggregometry. Clinical endpoints of death, MI, and TVR 
were also measured at 30 days. The study found that clopi-
dogrel reloading with 900 mg did have signifi cant increase in 
platelet inhibition compared to lower loading doses and there 
was no evidence of an absorption threshold which limited the 
benefi t of the 900 mg loading dose. There was no difference in 
the clinical endpoint between any of the dosing schemes. Thus 
although the study provided evidence for the use of a 900 mg 
loading dose in terms of platelet reactivity, the lack of clinical 
benefi t made the fi ndings diffi cult to interpret.
Overall, all of the above studies have suggested that a 
clopidogrel loading dose of 600 mg or 900 mg may be more 
benefi cial than a 300 mg loading dose in terms of reducing post-
PCI events. As most of these trials had small sample sizes, ACC/
AHA guidelines still offi cially considers clopidogrel 300 mg as 
an adequate loading dose but it does note that higher loading 
dose can be considered prior to PCI.24 The ongoing Clopidogrel 
Optimal Loading Dose Usage to Reduce Recurrent Events/
Optimal Antiplatelet Strategy for Interventions (OASIS-7) 
trial will randomize 14,000 high risk NSTE-ACS patients to 
300 mg versus 600 mg loading clopidogrel dose prior to PCI and 
should help further clarify the benefi t of higher loading doses 
in terms of short-term (30 days) post-PCI events.35
Personalized therapy
Much of the impetus for the higher dosing of clopidogrel is 
due to the wide variability of clopidogrel associated platelet 
inhibition, ie, the presence of clopidogrel resistance and its 
clinical implications. Hochholzer et al showed that in patients 
undergoing elective PCI who were pre-loaded with 600 mg 
clopidogrel, the degree of platelet inhibition as measured 
by ADP-induced optical aggregometry prior to intervention 
predicted the likelihood of post-PCI myocardial events.36 
Patients within the lower third and fourth quartile of platelet 
inhibition were at a signifi cantly higher risk of worse short-
term outcomes compared to those in the higher quartiles of 
platelet inhibition (Figure 7). This fi nding was also seen in 
the Antiplatelet Therapy for the Reduction of Myocardial 
Damage during Angioplasty – Platelet Reactivity Predicts 
Outcomes (ARMYDA-PRO) study which also assessed 
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platelet activity after a 600 mg loading clopidogrel dose but 
used a rapid cartridge based assay (VerifyNow P2Y12 Assay) 
rather than optical aggregometry.37
These studies led to the hypothesis that tailored therapy 
to overcome clopidogrel resistance could result in improved 
post-PCI outcomes. Although ADP-induced optical 
aggregometry is considered the gold standard in terms of 
assessing platelet function in patients receiving clopidogrel, 
it is a diffi cult test to perform at the bedside therefore its use 
in tailored therapy is limited.38 Additionally, ADP-induced 
optical aggregometry is somewhat non-specifi c as the effects 
of ADP on the P2Y1 receptor are included in this test but 
clopidogrel action does not involve this receptor. Schwarz 
et al found that the activity of clopidogrel and ticlopidine 
with its associated blockade of the P2Y12 receptor could be 
monitored through analysis of the intracellular vasodilator-
stimulated phosphoprotein (VASP) phosphorylation state.39 
Barragan et al used fl ow cytometry to quantitate the VASP 
phosphorylation state and developed the VASP index which 
is essentially a ratio of platelet activity that is inversely related 
to the effect of clopidogrel.40 This study also found that a 
VASP index greater than 50% was associated with a higher 
risk of subacute stent thrombosis.
Bonello et al prospectively examined the use of the tai-
lored clopidogrel dosing using the VASP index on post-PCI 
outcomes.41 This study initially measured the VASP index 
24 hours after a 600 mg clopidogrel loading dose in patients 
undergoing planned PCI for refractory angina, silent ischemia 
on stress testing, and NSTEMI. Patients with a VASP 
index 50% were offi cially enrolled in the study (N = 162) 
and were randomized to a control group (N = 84) versus 
further VASP-guided clopidogrel dosing (N = 78). In the 
control group, PCI was carried out without additional clopi-
dogrel. In the VASP-guided group, patients were given up to 
3 additional 600 mg clopidogrel doses in 24-hour increments 
until the VASP index was below 50%. The effect of each 
additional clopidogrel dose is shown in Figure 8. One-month 
follow-up demonstrated a signifi cant improvement in clinical 
outcomes with the control group having an overall major 
adverse cardiovascular event (MACE) rate of 10% including 
1 case of acute stent thrombosis and 3 cases of subacute stent 
thrombosis versus 0% in the VASP guided group (p = 0.007, 
Figure 9). This study provided clinical evidence for tailored 
clopidogrel therapy based on platelet activity but is limited 
by its small sample size. The ongoing Gauging Responsive-
ness With A VerifyNow Assay-Impact On Thrombosis 
And Safety (GRAVITAS) trial will compare outcomes in 
6600 patients randomized to tailored therapy using platelet 
functional testing versus standard therapy and should help 
clarify whether there is real benefi t to this approach.
Benefi t of clopidogrel 
and adjunctive therapies
All studies demonstrating the benefi t of clopidogrel in terms 
of reducing post-PCI myocardial necrosis have been against 
the background of aspirin use so dual antiplatelet therapy is 
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mandatory for optimal benefi t. Additionally antithrombotic 
use with heparin or enoxaparin was also routine in all stud-
ies demonstrating the benefi ts of clopidogrel in the setting 
of PCI. A meta-analysis by Sabatine et al42 examined the 
PCI-CURE, CREDO, and PCI-CLARITY trials and dem-
onstrated that there was added benefi t to pretreatment with 
clopidogrel regardless of the use glycoprotein IIB/IIIA 
inhibitors (GP IIB/IIIA inhibitors). This suggested that 
patients undergoing PCI who were started on GP IIB/IIIA 
inhibitors still benefi ted from the presence of clopidogrel 
loading in terms of reducing post-PCI events provided the 
dose was given adequately before the actual time of PCI. The 
Intracoronary Stenting and Anti-thrombotic Regimen: Rapid 
Early Action for Coronary Treatment (ISAR-REACT) trial 
demonstrated that in low risk patients, there is in fact no ben-
efi t, in terms of short term clinical post-PCI events, to adding 
GP IIB/IIIA inhibitors if clopidogrel loading with 600 mg is 
administered at least 2 hours prior to PCI. Thus in low risk 
patients, clopidogrel loading with 600 mg seems to provide 
adequate platelet activity inhibition with no need for further 
anti-platelet therapy.43 In contrast higher risks patients, as 
defi ned by the presence of positive troponins, do seem to 
have additional benefi t in terms of reduced post-PCI events 
when a GP IIB/IIIA inhibitor is used in addition to clopi-
dogrel pretreatment. This was demonstrated by the ISAR-
REACT 2 trial which enrolled 2022 patients presenting with 
100
50
0
VASP 1
(n = 78)
75
25
VA
SP
 In
de
x
VASP 2
(n = 78)
VASP 3
(n = 40)
VASP 4
(n = 26)
Figure 8 Effect of additional clopidogrel dosing on VASP Index. Reproduced with permission from Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses 
according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: 
a multicenter randomized prospective study.  J Am Coll Cardiol. 2008;51(14):1404–1411.41 Copyright © 2008 Elsevier.
Figure 9 One month clinical outcomes standard versus VASP-guided clopidogrel loading. Reproduced with permission from Bonello L, Camoin-Jau L, Arques S, et al.  Adjusted 
clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with 
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NSTE-ACS undergoing PCI after being loaded with 600 mg 
clopidogrel at least 2 hours prior to intervention.44 Patients 
were administered abciximab (N = 1012) versus placebo 
(N = 1010) in a double-blinded, randomized manner at the 
time of PCI. A composite of ischemic events (death, MI, 
urgent TVR) was assessed 30 days post PCI and found to be 
signifi cantly reduced in the abciximab group versus placebo 
(8.9% versus 11.9%, p = 0.03). This benefi t was limited only 
to patients with an elevated troponin. The ACUITY trial 
demonstrated that the use of the direct thrombin inhibitor 
bivalirudin was not inferior to the use of GP IIB/IIIA inhibi-
tor and enoxaparin or unfractionated heparin (UFH) in the 
management of patients presenting with NSTE-ACS with 
respect to 30-day rates of a composite endpoint of death, 
MI, or urgent TVR.45 Clopidogrel therapy was not mandated 
by protocol in either arm but a loading dose of 300 mg no 
later than 2 hours post-PCI and daily maintenance therapy 
of 75 mg was recommended. There was no signifi cant dif-
ference in the proportion of patients receiving clopidogrel 
therapy in the bivalirudin versus GP IIB/IIIA plus enoxa-
parin or UFH arms (64.2% versus 62.3% respectively). 
Subgroup analysis of this study suggested that patients on 
bivalirudin monotherapy who did not receive clopidogrel 
prior to PCI had increased ischemic events post-procedure 
compared to patients receiving GP IIB/IIIA and enoxaparin 
or UFH (9.1% versus 7.1%; 95% CI 1.03 to 1.63). This sug-
gested that use of bivalirudin in patients with NSTE-ACS 
requiring PCI should be limited to patients who have been 
pre-treated with clopidogrel. A subsequent post-hoc analysis 
by Lincoff et al46 found that as long as clopidogrel is admin-
istered before or within 30 minutes post-PCI, treatment with 
bivalirudin is equivalent (non-inferior) to enoxaparin or UFH 
and GP IIB/IIIA inhibitor in terms of short-term post-PCI 
ischemic outcomes.
Conclusion
Clopidogrel is an important pharmacologic agent used to 
reduce MI post-PCI as assessed directly by the evaluation 
of cardiac biomarkers post-intervention and indirectly by 
the evaluation of short term ischemic events. The optimal 
dose of clopidogrel is considered to be at least 300 mg given 
at least 6 to 15 hours prior to PCI but there is considerable 
evidence to suggest a loading dose of 600 mg given 2 to 
6 hours prior to PCI may be more effi cacious in limiting 
post-PCI events. Doses higher than 600 mg may be still 
more effi cacious especially in patients with evidence of 
clopidogrel resistance as assessed by platelet function test-
ing but this is controversial and requires further randomized 
testing to verify. The benefi t of clopidogrel therapy in the 
reduction of post-PCI ischemic events is independent and 
complementary to other adjunctive therapies including aspi-
rin, UFH/enoxaparin, GP IIB/IIIA, and bivalirudin.
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